Are you Dr. Gonzalez-Amado?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 20 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
210 E Grand Ave
South San Francisco, CA 94080Phone+1 610-551-2740Fax+1 310-301-8751
Summary
- Dr. Rafael Gonzalez-Amado, MD is a hematologist in South San Francisco, California. He is currently licensed to practice medicine in California.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1989 - 1992
Universidad de Cadiz Faculty of MedicineClass of 1987
Certifications & Licensure
CA State Medical License 1992 - 2026
Publications & Presentations
PubMed
- 9 citationsDetection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells.Barbra J Sasu, Gregory J Opiteck, Suhasni Gopalakrishnan, Vivek Kaimal, Tom Furmanak
Molecular Therapy. 2023-03-01 - 101 citationsSystemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcomaIndu R. Ramachandran, Daniel E. Lowther, Rebecca Dryer-Minnerly, Ruoxi Wang, Svetlana Fayngerts
Journal for Immunotherapy of Cancer. 2019-10-24 - 65 citationsLong-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.Edward A. Stadtmauer, Thomas H. Faitg, Daniel E. Lowther, Ashraf Badros, Karen Chagin
Blood Advances. 2019-07-09
Press Mentions
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)January 23rd, 2025- Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical CancerJanuary 15th, 2025
- ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung CancerOctober 24th, 2024
